BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial

Reuters

Yesterday

BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial

BioAge Labs Inc. announced additional positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant NLRP3 inhibitor developed for patients with cardiovascular risk factors. In the multiple ascending dose cohort, obese participants with elevated hsCRP receiving 120 mg once daily showed an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels. The study also reported significant reductions in IL-6 and fibrinogen. BGE-102 was well tolerated, with adverse events described as infrequent, mild to moderate, and self-limited, and no dose-limiting toxicities observed. Full Phase 1 data, including results from additional cohorts, are anticipated in the first half of 2026, and a Phase 2a study is planned to initiate in the same timeframe. Additional figures and data are available in the company's corporate presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623622) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602543210"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602543210\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602543210?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602543210","market":"us","top_or_hot":-1,"title":"BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BIOA\">BioAge Labs Inc.</a> announced additional positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant NLRP3 inhibitor developed for patients with cardiovascular risk factors. In the multiple ascending dose cohort, obese participants with elevated hsCRP receiving 120 mg once daily showed an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels. The study also reported significant reductions in IL-6 and fibrinogen. BGE-102 was well tolerated, with adverse events described as infrequent, mild to moderate, and self-limited, and no dose-limiting toxicities observed. Full Phase 1 data, including results from additional cohorts, are anticipated in the first half of 2026, and a Phase 2a study is planned to initiate in the same timeframe. Additional figures and data are available in the company's corporate presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623622) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BIOA\">BioAge Labs Inc.</a> announced additional positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant NLRP3 inhibitor developed for patients with cardiovascular risk factors. In the multiple ascending dose cohort, obese participants with elevated hsCRP receiving 120 mg once daily showed an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels. The study also reported significant reductions in IL-6 and fibrinogen. BGE-102 was well tolerated, with adverse events described as infrequent, mild to moderate, and self-limited, and no dose-limiting toxicities observed. Full Phase 1 data, including results from additional cohorts, are anticipated in the first half of 2026, and a Phase 2a study is planned to initiate in the same timeframe. Additional figures and data are available in the company's corporate presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623622) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL5wcRXT:1","article_id":"2602543210","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602543210","pubTimestamp":1768226512,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioAge Labs Inc. announced additional positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant NLRP3 inhibitor developed for patients with cardiovascular risk factors. In the multiple ascending dose cohort, obese participants with elevated hsCRP receiving 120 mg once daily showed an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels. The study also reported significant reductions in IL-6 and fibrinogen. BGE-102 was well tolerated, with adverse events described as infrequent, mild to moderate, and self-limited, and no dose-limiting toxicities observed. Full Phase 1 data, including results from additional cohorts, are anticipated in the first half of 2026, and a Phase 2a study is planned to initiate in the same timeframe. Additional figures and data are available in the company's corporate presentation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4588":"碎股","BIOA":"BioAge Labs Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4007":"制药"},"translate_title":"BioAge Labs报告BGE-102在1期试验中hsCRP降低86%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":0.9,"NDAQ":0.9},"content_text":"BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial\n    \n\nBioAge Labs Inc. announced additional positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant NLRP3 inhibitor developed for patients with cardiovascular risk factors. In the multiple ascending dose cohort, obese participants with elevated hsCRP receiving 120 mg once daily showed an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels. The study also reported significant reductions in IL-6 and fibrinogen. BGE-102 was well tolerated, with adverse events described as infrequent, mild to moderate, and self-limited, and no dose-limiting toxicities observed. Full Phase 1 data, including results from additional cohorts, are anticipated in the first half of 2026, and a Phase 2a study is planned to initiate in the same timeframe. Additional figures and data are available in the company's corporate presentation.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623622) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}